Roivant Sciences Ltd Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 9, 2026 results vs estimates
Roivant Sciences Ltd Forecast
Roivant Sciences Ltd short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 36.5% a year, a typical one-standard-deviation range is 35.59–39.45 over a week, 33.57–41.47 over a month and 23.82–51.22 over a year. (Signals as of 1 Nov 2026.)
Roivant Sciences Ltd Price Chart
Roivant Sciences Ltd Factors
YoY −2.5%
YoY +113.7%
YoY +20.1%
YoY −97.2%
YoY −53.2%
YoY +97.0%
YoY −4.3%
YoY −53.8%
YoY −53.8%
YoY +17.0%
YoY −33.3%
YoY +33.2%
Roivant Sciences Ltd fundamentals: income statement, balance sheet & cash flow
Roivant Sciences Ltd reported revenue of $8.3m and net income of -$299.8m in FY2026, the year ended 31 March 2026 — revenue down 71.6% and net income down 74.3% on the prior year. Free cash flow was -$758.6m. These figures are as reported in the filings, not restated: 8 fiscal years and 27 quarters of history, back to March 2019. 119 FINRA short-interest settlements are published alongside them, back to October 2021.
| USD millions | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Revenue | 8.3 | 29.1 | 32.7 | 31.5 | 55.3 |
| Cost of revenue | 1.3 | 0.9 | 1.6 | 3.0 | 9.0 |
| Gross profit | 7.0 | 28.1 | 31.1 | 28.5 | 46.3 |
| Research & development | 681.8 | 550.4 | 439.9 | 454.1 | 483.0 |
| Selling, general & admin. | — | — | — | — | 775.0 |
| Operating income | -515.1 | -1,003.3 | 4,497.0 | -906.8 | -1,211.7 |
| EBITDA | -261.2 | -667.5 | 4,624.7 | -838.2 | -910.8 |
| Interest expense | — | — | 34.8 | 28.0 | 7.0 |
| Pre-tax income | -264.6 | -681.6 | 4,567.9 | -885.0 | -923.7 |
| Income tax | 133.3 | 48.2 | 21.5 | 4.1 | 0.4 |
| Net income | -299.8 | -172.0 | 4,348.9 | -1,009.0 | -845.3 |
Download Roivant Sciences Ltd fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ROIV.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Roivant Sciences Ltd
Explore MacroFinance macro & markets research and analysis.
Roivant Sciences Ltd Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Roivant Sciences Ltd; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Roivant Sciences Ltd’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Roivant Sciences Ltd (United States)
Roivant Sciences Ltd is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Roivant Sciences Ltd?
What is the latest Roivant Sciences Ltd price?
Is Roivant Sciences Ltd in an uptrend?
How volatile is Roivant Sciences Ltd?
What factors affect Roivant Sciences Ltd?
Which trading strategies trade Roivant Sciences Ltd?
How are Roivant Sciences Ltd returns analysed?
Where can I download free Roivant Sciences Ltd historical data?
Free Roivant Sciences Ltd historical data (last 10 years)
Browse or instantly download the last 10 years of Roivant Sciences Ltd daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ROIV.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 38.655 |
| 2026-11-19 | 38.96 |
| 2026-11-18 | 38.73 |
| 2026-11-17 | 38.71 |
| 2026-11-16 | 38.61 |
| 2026-11-13 | 39.53 |
| 2026-11-12 | 39.99 |
| 2026-11-11 | 41.85 |
| 2026-11-10 | 41.19 |
| 2026-11-09 | 40.67 |
About this stock
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.